

# Moleculaire beeldvorming van de oestrogeenreceptor dichtheid om de hormonale behandelingsmogelijkheden voor patiënten met borstkanker te verbeteren.

Gepubliceerd: 01-03-2010 Laatste bijgewerkt: 18-08-2022

Measuring ER-density with FES-PET can be used as a predictive test to select patients sensitive for estrogen therapy.

<b>Ethische beoordeling</b>	Positief advies
<b>Status</b>	Werving gestart
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Observationeel onderzoek, zonder invasieve metingen

## Samenvatting

### ID

NL-OMON26431

### Bron

NTR

### Aandoening

breast cancer acquired anti-hormonal resistance

### Ondersteuning

**Primaire sponsor:** University Medical Center Groningen (UMCG), department of medical oncology

**Overige ondersteuning:** KWF

### Onderzoeksproduct en/of interventie

### Uitkomstmaten

#### Primaire uitkomstmaten

1 - Moleculaire beeldvorming van de oestrogeenreceptor dichtheid om de hormonale beh ... 5-05-2025

With a ROC analysis we will determine the optimal sensitivity and specificity of FES-PET in relation with the standard uptake value (SUV) to predict response to estrogen therapy.

## Toelichting onderzoek

### Achtergrond van het onderzoek

Patients with different types of acquired anti-hormonal resistance are likely to respond differently to a particular kind of treatment. The ER+ subtype would most likely initially respond to a second or third line of anti-hormonal therapy, but ultimately these tumors will again become resistant. At that stage, chemotherapy is the only treatment available. Chemotherapy is currently also the only treatment option for tumors of the ER- phenotype. In contrast, treatment with estrogen is highly effective for the hypersensitive ER++ phenotype and could therefore be an attractive alternative for chemotherapy in this selected group of patients. Currently, this treatment option is not utilized due to the absence of proper stratification methods.

FES-PET may allow identification of patients without ER expression (ER-), patients with preserved ER expression (ER+) and patients with ER overexpression (ER++). This project therefore aims to investigate in a pilot clinical study whether the acquired anti-hormonal resistant phenotypes in breast cancer patients can be discriminated on basis of ER expression levels as measured by FES-PET. The discrimination of phenotypes could allow selection of patients eligible to estrogen treatment.

### Doel van het onderzoek

Measuring ER-density with FES-PET can be used as a predictive test to select patients sensitive for estrogen therapy.

### Onderzoeksopzet

At the start of study ER density will be determined by FES-PET, the patient will be staged with CT-scan, and baseline clinical information will be collected (laboratory results, VAS-score, ECOG performance, ECG).

Follow-up will take place monthly during the first 3 months, and thereafter every 3 months.

### Onderzoeksproduct en/of interventie

In patients with acquired antihormonal resistance, eligible for estrogen therapy, a FES-PET scan will be made to determine FES-PET tumor uptake (which corresponds to estrogen receptor expression levels). Immediately after the FES-PET scan, all patients will start with a standard accepted dose of 2mg estradiol TID. Therapy response will be monitored by regular follow-up. RECIST criteria and clinical benefit will be used as criteria. In case of disease progression before end of the study period, estradiol treatment will be stopped.

# Contactpersonen

## Publiek

Dept. of Medical Oncology  
University Medical Center Groningen  
PO Box 30.001  
G.A.P. Hospers  
Groningen 9700 RB  
The Netherlands  
+31 (0)50 3616161

## Wetenschappelijk

Dept. of Medical Oncology  
University Medical Center Groningen  
PO Box 30.001  
G.A.P. Hospers  
Groningen 9700 RB  
The Netherlands  
+31 (0)50 3616161

# Deelname eisen

## Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Patients with the diagnosis of acquired anti-hormonal resistant advanced breast cancer showing progression after two or more lines of antihormonal treatment;
2. Treatment with estradiol will be started;
3. Age > 18 years;
4. ECOG performance status 0-2.

## Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Life Expectancy < 3 months;

2. Uncontrolled CNS metastases;
3. History of thrombosis;
4. Uncontrolled hypercalcemia;
5. Treatment with any investigational drug within 30 days before start of study;
6. Serious uncontrolled concurrent illness, e.g. autoimmune disorders;
7. New York Heart Association (NYHA) class III/IV congestive heart failure;
8. Dyspnea at rest due to any cause;
9. Pregnant or lactating women. Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause;
10. Women of childbearing potential unless a) surgically sterile or b) using adequate measures of contraception.

## Onderzoeksopzet

### Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blinding:	Dubbelblind
Controle:	N.v.t. / onbekend

### Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	01-02-2010
Aantal proefpersonen:	50
Type:	Verwachte startdatum

## Ethische beoordeling

Positief advies

Datum: 01-03-2010

Soort: Eerste indiening

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

Register	ID
NTR-new	NL2117
NTR-old	NTR2234
Ander register	METc UMCG : 2008.277
ISRCTN	ISRCTN wordt niet meer aangevraagd.

## Resultaten

### Samenvatting resultaten

1. Dehdashti F, Mortimer JE, Trinkaus K. et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. *Breast Cancer Res Treat* (2009) 113:509-517;<br>
2. Ellis MJ, Dehdashti F, Kommareddy A et al. A randomized phase 2 trial of low dose (mg daily) versus high dose (30mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. *Breast Cancer Symposium 2008 San Antonio*.